Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2021.06.16.448746

Fyn kinase inhibition using AZD0530 improves recognition memory and reduces depressive-like behaviour in an experimental model of Parkinson's disease

Guglietti, B. L.·Carr, L.·Ellul, B.·Mustafa, S.·Corrigan, F.·Collins-Praino, L. E.
View original source ↗Export metadata ↓

Abstract

Fyn kinase has recently been established as a major upstream regulator of neuroinflammation in PD. This study aimed to determine if inhibition of Fyn kinase could lead to reduced neuroinflammation and improvements in motor and non-motor impairments in an early-stage model of PD. An experimental model of PD was produced using intra-striatal injection (4{micro}l) of the neurotoxin 6-OHDA (5{micro}g/{micro}l). Sprague Dawley rats (n=42) were given either vehicle, 6mg/kg or 12mg/kg of Fyn kinase inhibitor (AZD0530) daily for 32 days via oral gavage and tested on a battery of tasks assessing motor, cognitive and neuropsychiatric outcomes. AZD 0530 administration led to improvement in volitional locomotion and recognition memory, as well as a reduction in depressive-like behaviour. Pathologically, an inflammatory response was observed; however, there were no significant differences in markers of neuroinflammation between treatment groups. Taken together, results indicate a potential therapeutic benefit for use of Fyn kinase inhibition to treat non-motor symptoms of PD, although mechanisms remain to be elucidated. HIGHLIGHTSO_LIFyn kinase has recently been proposed as a major upstream regulator of microglial activation in Parkinsons disease (PD). C_LIO_LIThis study was the first to evaluate the effects of Fyn kinase inhibition in a rodent model of PD. C_LIO_LIFyn kinase inhibition using the Fyn kinase inhibitor AZD 0530 was capable of improving volitional locomotion and recognition memory and reducing depressive-like behaviour in a rodent model of PD. C_LIO_LIInterestingly, while increases in microglial activation were observed in this rodent model of PD, AZD 0530 did not significantly reduce this activation. C_LIO_LIThis suggests that the behavioural improvements associated with Fyn kinase inhibition may occur independently of neuroinflammation and may be attributable to other brain mechanisms, including actions on NMDA or 5-HT6 receptors. C_LI

Explore related subjects

neurosciencePreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Guglietti, B. L., Carr, L., Ellul, B., Mustafa, S., Corrigan, F., Collins-Praino, L. E.. 2021-06-17. Fyn kinase inhibition using AZD0530 improves recognition memory and reduces depressive-like behaviour in an experimental model of Parkinson's disease. https://doi.org/10.1101/2021.06.16.448746

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Distinguishing evidence accumulation from choice confidence in neural signatures of perceptual decision making

Human electrophysiology research has identified the centro-parietal positivity (CPP) as an apparent neural correlate of sensory evidence accumulation during perceptual decision-making. The CPP has also been shown to closely scale with subjective confidence. Coupled with the fact of its domain-generality and lack of choice selectivity, this observation raises the possibility that the CPP might in fact trace subjective confidence rather than cumulative evidence, two quantities that are closely correlated in most experiments. To disentangle confidence from cumulative evidence, we used predictive cues with 80% validity to manipulate prior expectations of participants during a contrast discrimination task while recording electroencephalography (EEG). At the time of decision termination, confidence is expected to reach a higher level for validly cued versus invalidly cued choices, whereas the opposite would be expected of a cumulative evidence signal due to biased decision starting points. As expected, valid cues led to faster, more accurate and more confident responses compared to invalid and neutral cues. At the neural level, cues produced systematic increases in preparation of the expected action prior to evidence onset as indexed by premotor mu/beta activity, consistent with cue-biased criterion adjustments. The pre-response CPP amplitude was significantly reduced for validly cued choices and the effect remained even when matching for confidence. Together these findings suggest that the CPP is not a direct read-out of subjective confidence, but an evidence accumulation signal that contributes to both decision formation and confidence estimation.

neuroscience↗
bioRxiv2026

A Neurocompliant Ionic Conductive Hydrogel Orchestrates Glial and Vascular Remodeling to Mitigate Traumatic Brain Injury

Developing conductive scaffolds for neural regeneration is often hindered by the cytotoxicity and mechanical mismatch inherent to conventional electronic fillers. Here, we report an ultrasoft ionically conductive hydrogel engineered by grafting choline-based bioionic liquids (BIL) onto fish gelatin (FiBGel). Systematic optimization yields brain-mimetic conductivity (0.25-0.68 S/m), elastic moduli (0.6-0.9 kPa), and physiological water content (72-81%). In 3D culture, the matrix drives spontaneous neurogenesis, achieving ~90% MAP2+ neurons with robust calcium signaling, while concurrently supporting endothelial network formation. We report the first intracerebral administration of a BIL hydrogel, demonstrating remarkable biocompatibility and immunomodulation. In a traumatic brain injury model, a single FiBGel dose halves reactive astrogliosis, enhances cortical revascularization, and limits lesion cavity expansion. Leveraging an FDA-recognized micronutrient, FiBGel offers a translatable strategy that integrates neuromechanics, conductivity, immune modulation, and vascular support within one injectable scaffold for minimally invasive treatment of brain injuries.

neuroscience↗
bioRxiv2026

Changes in anterior cingulate connectivity associated with response to antidepressant treatment for major depressive disorder

Background: Resting-state functional connectivity (rsFC) involving the anterior cingulate cortex (ACC) and the hippocampal formation has been implicated in major depressive disorder (MDD) and antidepressant response. However, it remains unclear whether connectivity changes in distinct ACC subdivisions and hippocampal formation reflect general antidepressant effects or are specifically associated with clinical improvement. Methods: Forty-one, unmedicated adults with MDD underwent functional MRI before and after 8 weeks of sertraline or bupropion treatment. Seed-based rsFC analyses examined subgenual ACC (sgACC), pregenual ACC (pgACC), dorsal ACC (dACC), and hippocampal formation connectivity. Linear mixed-effects models tested whether connectivity change was associated with treatment response, remission, and dimensional improvement in depressive symptoms. Results: Thirty individuals (73.2%) responded to treatment and 26 (63.4%) achieved remission. Overall, rsFC decreased pre- to post-treatment between (1) dACC and pgACC (but not sgACC and hippocampal formation) and (2) cortical regions primarily involving default mode and frontoparietal networks. When considering treatment response, differences in sgACC and pgACC connectivity with temporal and inferior frontal regions emerged (increased in responders vs. decreased in non-responders). Remission was similarly associated with increased sgACC connectivity with temporal and prefrontal regions, and increased sgACC connectivity with temporal cortical regions related to greater reductions in depressive symptoms. Conclusions: Antidepressant treatment was associated with distinct patterns of ACC connectivity change, with general reductions in dorsal and pregenual connectivity but increases in subgenual and pregenual connectivity associated with favorable clinical outcomes. Findings suggest that changes in sgACC/pgACC connectivity are particularly relevant to antidepressant treatment response. Keywords: Major depressive disorder; Resting-state functional connectivity; Anterior cingulate cortex; Antidepressant treatment; Treatment response; Subgenual anterior cingulate cortex.

neuroscience↗